High expression of RAD51 promotes DNA damage repair and survival in KRAS-mutant lung cancer cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
RAD51 recombinase plays a critical role in homologous recombination and DNA damage repair. Here we showed that expression of RAD51 is frequently upregulated in lung cancer tumors compared with normal tissues and is associated with poor survival (hazard ratio (HR) = 2, P = 0.0009). Systematic investigation of lung cancer cell lines revealed higher expression of RAD51 in KRAS mutant (MT) cells compared to wildtype (WT) cells. We further showed that MT KRAS, but not WT KRAS, played a critical role in RAD51 overexpression via MYC. Moreover, our results revealed that KRAS MT cells are highly dependent on RAD51 for survival and depletion of RAD51 resulted in enhanced DNA double strand breaks, defective colony formation and cell death. Together, our results suggest that mutant KRAS promotes RAD51 expression to enhance DNA damage repair and lung cancer cell survival, suggesting that RAD51 may be an effective therapeutic target to overcome chemo/radioresistance in KRAS mutant cancers.
Abstract
RAD51 recombinase plays a critical role in homologous recombination and DNA damage repair. Here we showed that expression of RAD51 is frequently upregulated in lung cancer tumors compared with normal tissues and is associated with poor survival (hazard ratio (HR) = 2, P = 0.0009). Systematic investigation of lung cancer cell lines revealed higher expression of RAD51 in KRAS mutant (MT) cells compared to wildtype (WT) cells. We further showed that MT KRAS, but not WT KRAS, played a critical role in RAD51 overexpression via MYC. Moreover, our results revealed that KRAS MT cells are highly dependent on RAD51 for survival and depletion of RAD51 resulted in enhanced DNA double strand breaks, defective colony formation and cell death. Together, our results suggest that mutant KRAS promotes RAD51 expression to enhance DNA damage repair and lung cancer cell survival, suggesting that RAD51 may be an effective therapeutic target to overcome chemo/radioresistance in KRAS mutant cancers.
참고문헌 (28)
- Blandin Knight S, "Progress and prospects of early detection in lung cancer", Open Biol, 7, pp.170070~ (2017)
- Kaufman J, "Treatment of KRAS-Mutant Non-Small Cell Lung Cancer : The End of the Beginning for Targeted Therapies", JAMA, 317, pp.1835~1837 (2017)
- Matikas A, "Targeting KRAS mutated non-small cell lung cancer : A history of failures and a future of hope for a diverse entity", Crit Rev Oncol Hematol, 110, pp.1~12 (2017)
- Cox AD, "Targeting RAS membrane association: back to the future for anti-RAS drug discovery?", Clin Cancer Res, 21, pp.1819~1827 (2015)
- De Roock W, "KRAS, BRAF, PIK3CA, and PTEN mutations : implications for targeted therapies in metastatic colorectal cancer", Lancet Oncol, 12, pp.594~603 (2011)
- Petermann E, "Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair", Mol Cell, 37, pp.492~502 (2010)
- Zafar F, "Homologous recombination contributes to the repair of DNA double-strand breaks induced by highenergy iron ions", Radiat Res, 173, pp.27~39 (2010)
- Su F, "Nonenzymatic role for WRN in preserving nascent DNA strands after replication stress", Cell Rep, 9, pp.1387~1401 (2014)
- Alshareeda AT, "Clinical and biological significance of RAD51expression in breast cancer : a key DNA damage response protein", Breast Cancer Res Treat, 159, pp.41~53 (2016)
- Nagathihalli NS, "RAD51 as a potential biomarker and therapeutic target for pancreatic cancer", Biochim Biophys Acta, 1816, pp.209~218 (2011)
- Maacke H, "DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma", Oncogene, 19, pp.2791~2795 (2000)
- Balbous A, "A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells", BMC Cancer, 16, pp.604~ (2016)
- Kalimutho M, "Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae", Mol Oncol, 11, pp.470~490 (2017)
- Roman M, "KRAS oncogene in non-small cell lung cancer : clinical perspectives on the treatment of an old target", Mol Cancer, 17, pp.33~ (2018)
- Eder S, "Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K(hnRNP K)", Cancer Lett, 385, pp.160~167 (2017)
- Eilers M, "Myc's broad reach", Genes Dev, 22, pp.2755~2766 (2008)
- Ischenko I, "KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents", Oncotarget, 8, pp.17995~18009 (2017)
- Perera D, "Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYCdependent sensitivity to anti-mitotic agents", Sci Rep, 6, pp.29741~ (2016)
- Grabocka E, "Molecular pathways : targeting the dependence of mutant RAS cancers on the DNA damage response", Clin Cancer Res, 21, pp.1243~1247 (2015)
- Dietlein F, "A Synergistic Interaction between Chk1-and MK2 Inhibitors in KRAS-Mutant Cancer", Cell, 162, pp.146~159 (2015)
- Zhao L, "Association between genetic variants in DNA doublestrand break repair pathways and risk of radiation therapy-induced pneumonitis and esophagitis in nonsmall cell lung cancer", Cancers (Basel), 8, pp.E23~ (2016)
- Scarbrough PM, "A cross-cancer genetic association analysis of the DNA repair and DNA damage signaling pathways for lung, ovary, prostate, breast, and colorectal cancer", Cancer Epidemiol Biomarkers Prev, 25, pp.193~200 (2016)
- Rothschild SI, "Biomarkers of DNA repair and related pathways : significance in non-small cell lung cancer", Curr Opin Oncol, 23, pp.150~157 (2011)
- O'Grady S, "The role of DNA repair pathways in cisplatin resistant lung cancer", Cancer Treat Rev, 40, pp.1161~1170 (2014)
- Chen P, "The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells", Cell Oncol(Dordr), 39, pp.511~522 (2016)
- Soucek L, "Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice", Genes Dev, 27, pp.504~513 (2013)
- Luoto KR, "Tumor cell kill by c-MYC depletion : role of MYC-regulated genes that control DNA double-strand break repair", Cancer Res, 70, pp.8748~8759 (2010)
- Tang Z, "GEPIA : a web server for cancer and normal gene expression profiling and interactive analyses", Nucleic Acids Res, 45, pp.W98~W102 (2017)[DOI]